

RECEIVED

JUN 14 2002

TECH CENTER 600/2900

CU identifying the location of the premalignant or malignant cells bound to said compound within the at least one breast duct or ductal network.

D1
C2 5. (Twice Amended) A method of identifying the location of premalignant or malignant cells within a breast duct or breast ductal network, said method comprising:
providing a premalignant or malignant cancer cell specific identifying agent;
delivering the identifying agent through at least one breast duct;
allowing the delivered identifying agent to bind to premalignant or malignant cells within said at least one duct or ductal network and unbound portions of the delivered identifying agent to be eliminated from said at least one duct; and
identifying the location of the premalignant or malignant cells bound to said identifying agent within the at least one breast duct or ductal network.

D1
C3 9. (Twice Amended) A method of determining the lymph node involvement in patients diagnosed with premalignant or malignant breast cancer growths, said method comprising:
providing a compound comprising an identifying agent coupled to a targeting agent;
delivering the compound through at least one breast duct;
allowing the delivered compound to bind to premalignant or malignant cells within said lymph nodes and unbound portions of the delivered compound to be eliminated from said at least one duct;
determining the lymph node involvement after said unbound portions of the delivered compound have exited said at least one breast duct; and
identifying the location of said lymph node involvement.

D1
C4 13. (Twice Amended) A method of determining the lymph node involvement in patients diagnosed with premalignant or malignant breast cancer growths, said method comprising: